Longevica Therapeutics Named New Scientific Advisory Board
The San Francisco biotech firm appointed an advisory board as it shifts from discovery to clinical development.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you trust private biotech companies to successfully develop credible treatments to extend human lifespan?
Longevica Therapeutics has formed a new Scientific Advisory Board and named Dr. Prasun Mishra as its Chief Executive Officer. The company is pivoting its operations toward clinical execution for age-related diseases.
Why it matters
The board formation signals a transition from foundational discovery to clinical application for the San Francisco-based biotech. Investors and residents are waiting to see if the company's proprietary screening data will successfully translate into human therapeutic development.
Longevica backed its research with a $13 million investment in a four-year mammalian screening program that tracked 16,000 subjects. The company reports that its tested compounds yielded a 10% to 22% increase in mammalian lifespan.
The players
Longevica Therapeutics
A biotechnology company headquartered in San Francisco that develops lifespan-extending compounds.
Dr. Prasun Mishra
The newly appointed Chief Executive Officer of Longevica Therapeutics.
The details
Longevica utilizes machine learning algorithms trained on outcomes from full-lifespan mammalian screenings conducted at The Jackson Laboratory. By formalizing its scientific leadership, the company intends to move two classes of therapeutics, designed to treat age-related conditions, toward clinical trials. Longevica operates with headquarters in both San Francisco and New York.
Timeline
September 29, 2026: The company announced the board formation.
Across the Bay
Longevica's move mirrors the broader biotech industry trend of shifting high-throughput screening data into regulated clinical environments. The company relies on massive biological datasets collected at The Jackson Laboratory to anchor its path toward commercial therapeutic development.
As the firm transitions toward clinical execution, local residents should monitor for updates on trial enrollment opportunities. The move marks a change in strategy for the San Francisco-headquartered company as it prepares for future regulatory milestones.
The takeaway
Longevica is shifting its focus from raw data discovery to developing compounds aimed at extending healthspan. Interested parties should keep an eye on the company's official pipeline announcements for news regarding future clinical study targets.
Further reading
For more updates on local life sciences developments, visit our Biotech section.
More information
View the current Longevica company pipeline and research on their official site.
Live Poll
Do you trust private biotech companies to successfully develop credible treatments to extend human lifespan?
